Melanoma News and Research

Latest Melanoma News and Research

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

An experimental drug designed to treat cancers with a particular genetic fault has shown promising results in a small clinical trial.

27 Aug 2010

V Foundation Wine Celebration raises fund for cancer research

The 12th Annual Wine Celebration benefitting The V Foundation took place August 6&7 in Napa Valley, raising $2.2 million for cancer research. The event, a signature fundraiser for sportscaster/coach Jim Valvano's eponymous foundation, has raised more than $35 million since 1998.

27 Aug 2010

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

CreAgri, Inc. announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.

25 Aug 2010

BioAlliance Pharma launches Oravig drug in the U.S. market

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc..

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

mBeach Software issues stockholder update for skin cancer diagnostic solutions

mBeach Software Inc. today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

21 Aug 2010

Melanoma Research Alliance announces grant to support six research programs

The Melanoma Research Alliance today announced $5.2 million in grants to support six multidisciplinary teams pursuing innovative, translational research approaches designed to benefit melanoma patients.

21 Aug 2010

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of Cancer.

20 Aug 2010

TOPEX announces sale of skin cancer business operations to SENSUS Healthcare

TOPEX, Inc. announces the sale of its skin cancer business operations to SENSUS Healthcare, LLC for its low energy SRT 100 superficial radiotherapy treatment system. Since TOPEX received FDA approval during 2007, many systems have been operating worldwide at hospital radiation oncology centers, dermatology and veterinary oncology practices for the treatment of skin cancer.

19 Aug 2010

FDA accepts to review Bristol-Myers Squibb's ipilimumab for melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted a priority review designation by the FDA.

19 Aug 2010

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Looking to gain further understanding about the impact of cancer on patients and families, The Cancer Institute of New Jersey (CINJ) is expanding its Quality and Outcomes in Cancer Care (QOCC) Research Program by welcoming nationally-recognized population science researcher Sharon Manne, PhD. Dr. Manne, who is the recipient of major grant awards from the National Institutes of Health (NIH) for her work in behavioral science, was most recently at the Fox Chase Cancer Center in Philadelphia. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

17 Aug 2010

Diets rich in antioxidants, omega-3 fatty acids can help protect people from skin cancer: Study

We all want that summer glow that comes from a day at the beach, but taking in the rays can have long-term implications for our health. Now Dr. Niva Shapira of Tel Aviv University's School of Health Professions suggests a way to make fun in the sun safer ― and it's all in our food.

17 Aug 2010

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Copper deficiency diseases can be devastating. Symptoms can range from crippling neurological degeneration in Menkes disease ,a classic copper deficiency disease to brittle bones, anaemia and defective skin pigmentation in gastric bypass patients. Unfortunately, very little is known about how the body uses this essential nutrient. Knowing that melanocytes (the cells that give rise to hair, skin and eye pigmentation) are dramatically affected by the effects of copper deficiency, Elizabeth Patton from the University of Edinburgh, UK, and other colleagues from UK and US based labs decided to find out how melanocytes metabolise copper.

17 Aug 2010

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma.

16 Aug 2010

Melanoma News and Research

Latest Melanoma News and Research

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

V Foundation Wine Celebration raises fund for cancer research

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Treating metastatic melanoma tumors with specific genetic signature shows promising results

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

BioAlliance Pharma launches Oravig drug in the U.S. market

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

mBeach Software issues stockholder update for skin cancer diagnostic solutions

Melanoma Research Alliance announces grant to support six research programs

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

TOPEX announces sale of skin cancer business operations to SENSUS Healthcare

FDA accepts to review Bristol-Myers Squibb's ipilimumab for melanoma

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Diets rich in antioxidants, omega-3 fatty acids can help protect people from skin cancer: Study

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Melanoma News and Research

Latest Melanoma News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in